This might be in part mediated by a hepatic steatosis-associated reduced LDL uptake via the LDL receptor (40), potentially mediated by increased proprotein convertase 9 activity and subsequent LDL-receptor degradation (41-43). This evidence concerns the gene PCSK9 and fatty liver disease.